Page 47 - 2022_03-Haematologica-web

Genome complexity in CLL: karyotype versus microarrays
Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenet- ics and fluorescence in situ hybridization techniques? Leuk Lymphoma. 2013;54(5): 986-995.
30. Urbankova H, Papajik T, Plachy R, et al. Array-based karyotyping in chronic lym- phocytic leukemia (CLL) detects new unbal- anced abnormalities that escape convention- al cytogenetics and CLL FISH panel. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(1):56-64.
31.Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107(2):742-751.
32. Heerema NA, Muthusamy N, Zhao Q, et al. Prognostic significance of translocations in the presence of mutated IGHV and of cyto- genetic complexity at diagnosis of chronic lymphocytic leukemia. Haematologica. 2021;106(6):1608-1615.
33. Puente XS, Beà S, Valdés-Mas R, et al. Non- coding recurrent mutations in chronic lym- phocytic leukaemia. Nature. 2015;526 (7574):519-524.
34. Salaverria I, Martín-Garcia D, López C, et al. Detection of chromothripsis-like patterns
with a custom array platform for chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2015;54(11):668-680.
35. O’Brien S, Furman RR, Coutre S, et al. Single agent ibrutinib in treatment-naıve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910-1919.
36. Kreuzer KA, Furman RR, Stilgenbauer S, et al. Outcome of patients with complex karyotype in a phase 3 randomized study of idelalisib plus rituximab for relapsed chronic Lymphocytic Leukemia. Blood. 2016;128 (22):192.
37. Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RES- ONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32(1):83- 91.
38.Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511- 1517.
39. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoim- munotherapy in older patients with untreat-
ed CLL. N Engl J Med. 2018;379(26):2517-
2528.
40. Kipps TJ, Fraser G, Coutre SE, et al. Long-
term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2019;19(11): 715-722.
41. Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with pre- viously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353-1363.
42.Al-Sawaf O, Lilienweiss E, Bahlo J, et al. High efficacy of venetoclax plus obinu- tuzumab in patients with complex kary- otype and chronic lymphocytic leukemia. Blood. 2020;135(11):866-870.
43. Kreuzer KA, Furman RR, Stilgenbauer S, et al. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia. 2020;34(1):296-300.
44. Jondreville L, Krzisch D, Chapiro E, Nguyen- Khac F. The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. Am J Hematol. 2020;95(11):1361-1367.
haematologica | 2022; 107(3)
603